Literature DB >> 10347791

The role of natural killer cells in the early period of infection in murine cutaneous leishmaniasis.

M D Laurenti1, M Gidlund, D M Ura, I L Sinhorini, C E Corbett, H Goto.   

Abstract

In order to study the role of natural killer (NK) cells during the early period of Leishmania infection, BALB/c mice were selectively and permanently depleted of NK cells by injection with 90Sr and subsequently infected with Leishmania (Leishmania) amazonensis (HSJD-1 strain). 90Sr is known to selectively deplete NK cells, leaving an intact T- and B-cell compartment and preserving the ability to produce both interferon alpha and IL-2. This method of depletion has advantages when compared with depletion using anti-NK cell monoclonal antibodies because the effect is permanent and neither activates complement nor provokes massive cell death. In the present study, after one month of treatment with 90Sr, the depletion of NK cells was shown by a more than ten-fold reduction in the cytotoxic activity of these cells: 2 x 10(6) spleen cells from NK-depleted animals were required to reach the same specific lysis of target cells effected by 0.15 x 10(6) spleen cells from normal control animals. The histopathology of the skin lesion at 7 days after Leishmania infection showed more parasites in the NK cell-depleted group. This observation further strengthens a direct role of NK cells during the early period of Leishmania infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10347791     DOI: 10.1590/s0100-879x1999000300012

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  10 in total

1.  Leishmania-infected macrophages are targets of NK cell-derived cytokines but not of NK cell cytotoxicity.

Authors:  Chittappen K Prajeeth; Simone Haeberlein; Heidi Sebald; Ulrike Schleicher; Christian Bogdan
Journal:  Infect Immun       Date:  2011-04-25       Impact factor: 3.441

2.  Effects of exogenous transforming growth factor beta on Trypanosoma congolense infection in mice.

Authors:  Boniface Namangala; Chihiro Sugimoto; Noboru Inoue
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

3.  Immunological perspectives of leishmaniasis.

Authors:  Susanne Nylén; Shalini Gautam
Journal:  J Glob Infect Dis       Date:  2010-05

4.  Role of natural killer cells in modulating dendritic cell responses to Leishmania amazonensis infection.

Authors:  Mayra X Hernandez Sanabria; Diego A Vargas-Inchaustegui; Lijun Xin; Lynn Soong
Journal:  Infect Immun       Date:  2008-09-15       Impact factor: 3.441

5.  Protective immunity and vaccination against cutaneous leishmaniasis.

Authors:  Ifeoma Okwor; Zhirong Mou; Dong Liu; Jude Uzonna
Journal:  Front Immunol       Date:  2012-05-29       Impact factor: 7.561

Review 6.  Cytotoxic activity in cutaneous leishmaniasis.

Authors:  Taís M Campos; Rúbia Costa; Sara Passos; Lucas P Carvalho
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-11       Impact factor: 2.743

Review 7.  Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.

Authors:  Alti Dayakar; Sambamurthy Chandrasekaran; Suresh V Kuchipudi; Suresh K Kalangi
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

Review 8.  Cutaneous Leishmaniasis: The Complexity of Host's Effective Immune Response against a Polymorphic Parasitic Disease.

Authors:  Áurea Gabriel; Ana Valério-Bolas; Joana Palma-Marques; Patrícia Mourata-Gonçalves; Pedro Ruas; Tatiana Dias-Guerreiro; Gabriela Santos-Gomes
Journal:  J Immunol Res       Date:  2019-12-01       Impact factor: 4.818

Review 9.  Natural killer cells in experimental and human leishmaniasis.

Authors:  Christian Bogdan
Journal:  Front Cell Infect Microbiol       Date:  2012-05-29       Impact factor: 5.293

Review 10.  Review on the Role of Host Immune Response in Protection and Immunopathogenesis during Cutaneous Leishmaniasis Infection.

Authors:  Teshager Dubie; Yasin Mohammed
Journal:  J Immunol Res       Date:  2020-06-18       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.